Today, California-based Mirum Pharmaceuticals, Inc. announced it will acquire Bluejay Therapeutics in a deal valued at up to $820 million.
The deal will grant Mirum worldwide rights to brelovitug, a monoclonal antibody being tested for chronic hepatitis D— a rare and severe liver condition affecting approximately 230,000 people in the United States and Europe, with no currently approved treatments.
Under the terms of the definitive agreement, Mirum has agreed to acquire all outstanding shares of Bluejay for $250 million in cash and $370 million in Mirum common stock, along with potential tiered sales-based milestone payments of up to $200 million in cash.
Chris Peetz, Chief Executive Officer of Mirum Pharmaceuticals told investors, “This acquisition fits squarely with what we do best – advancing high-impact medicines for patients with rare diseases through disciplined development, regulatory innovation, and commercial excellence… The Bluejay team has done commendable work advancing brelovitug to this stage and we look forward to building on that progress to bring this important new treatment to people living with HDV.”
Keting Chu, Founder and CEO of Bluejay Therapeutics said, “Bluejay was founded to develop transformative therapies for people with viral and liver diseases and, working with regulatory agencies, such as the FDA and the European Medicines Agency, the Bluejay team developed brelovitug from clinical development candidate to global Phase 3 trial in four years. Brelovitug has the potential to redefine HDV treatment, and Mirum’s rare disease leadership, commitment to rare liver communities and commercialization expertise make it the right company to carry this program forward globally.”
The transaction with Bluejay has received approval from the Boards of Directors of both companies and is expected to close in the first quarter of 2026.
By CEO NA Editorial Staff
